Table 2.
Association of anthropometric measures and MetS with all-cause and BC-specific mortality, overall and by menopausal status, Naples, Italy, 2009-2022.
| All | Pre-menopausal | Post-menopausal | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deaths from all-causes | Deaths from breast cancer | Deaths from all-causes | Deaths from breast cancer | Deaths from all-causes | Deaths from breast cancer | |||||||
| HR* (95% CI) | p** | HR* (95% CI) | p** | HR* (95% CI) | p** | HR (95% CI) | p** | HR* (95% CI) | p** | HR (95% CI) | p** | |
| Body mass index, kg/m2 | 0.345 | 0.029 | 0.291 | 0.090 | 0.277 | 0.032 | ||||||
| < 25 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| 25–30 | 0.99 (0.67-1.47) | 1.03 (0.62-1.73) | 1.79 (0.77-4.13) | 2.44 (1.00-5.95) | 0.73 (0.48-1.12) | 0.52 (0.28-0.98) | ||||||
| ≥ 30 | 1.25 (0.85-1.84) | 1.72 (1.06–2.78) | 1.91 (0.70–5.26) | 2.60 (0.90–7.48) | 0.95 (0.63–1.41) | 1.06 (0.62–1.79) | ||||||
| Per 5 U | 1.17 (1.02–1.34) | 0.030 | 1.31 (1.11–1.55) | 0.002 | 1.43 (1.04–1.96) | 0.028 | 1.58 (1.15–2.18) | 0.005 | 1.06 (0.91–1.23) | 0.457 | 1.15 (0.94–1.41) | 0.189 |
| Waist circumference, cm | 0.053 | 0.014 | 0.007 | 0.006 | 0.926 | 0.536 | ||||||
| < 88 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| ≥ 88 | 1.39 (1.00–1.94) | 1.71 (1.12–2.61) | 2.94 (1.35–6.42) | 3.09 (1.37–6.94) | 1.02 (0.71–1.46) | 1.17 (0.72–1.89) | ||||||
| Per 10 U | 1.16 (1.05–1.29) | 0.005 | 1.24 (1.10–1.40) | 0.001 | 1.33 (1.01–1.76) | 0.046 | 1.39 (1.05–1.86) | 0.023 | 1.09 (0.97–1.23) | 0.141 | 1.15 (0.99–1.34) | 0.065 |
| Waist-to-hip ratio, u | 0.011 | 0.014 | 0.036 | 0.035 | 0.367 | 0.395 | ||||||
| ≤ 0.85 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| > 0.85 | 1.62 (1.12–2.37) | 1.80 (1.13–2.86) | 2.38 (1.06–5.33) | 2.46 (1.06–5.71) | 1.21 (0.80–1.84) | 1.27 (0.73–2.20) | ||||||
| Per 0.1 U | 1.27 (1.07–1.50) | 0.005 | 1.33 (1.08–1.63) | 0.007 | 1.54 (0.91–2.60) | 0.105 | 1.61 (0.93–2.77) | 0.089 | 1.12 (0.92–1.36) | 0.246 | 1.15 (0.90–1.47) | 0.254 |
| Metabolic syndrome (MetS) | 0.010 | 0.010 | 0.463 | 0.476 | 0.193 | 0.103 | ||||||
| No | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Yes | 1.61 (1.12–2.32) | 1.81 (1.51–2.85) | 1.79 (0.38–8.47) | 1.76 (0.37–8.38) | 1.29 (0.88–1.89) | 1.50 (0.92–2.45) | ||||||
| MetS components | 0.001 | 0.008 | 0.170 | 0.218 | 0.099 | 0.150 | ||||||
| None | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| 1–2 | 2.92 (1.44–5.91) | 2.45 (1.15–5.25) | 2.99 (0.95–9.44) | 2.79 (0.87–8.91) | 2.39 (0.95–6.01) | 2.09 (0.73–5.95) | ||||||
| ≥ 3 | 3.94 (1.88–8.26) | 3.60 (1.60–8.11) | 2.76 (0.45–16.89) | 2.55 (0.42–15.63) | 2.77 (1.09–7.06) | 2.73 (0.95–7.84) | ||||||
*Cox proportional hazard ratio (HR) adjusted by terms of: age (≤ 40, 41–60, > 60), center (IRCCS G. Pascale, Policlinico Federico II), cancer stage (I–IIA, IIB, IIIA–IIIC) and molecular subtypes (Luminal A, Luminal B, HER 2+, TN); **For the entire variable the p-value refers to Wald Test, for numerical variable z-Test p-value was reported.
Significant results are shown in bold.